INBXInhibrx Biosciences Inc.
−23.4% today · +7.0% over a year
No score: too little data.
Priced higher than most peers. No dividend.
Inhibrx Biosciences Inc. (INBX) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €968.9M. Over the past 12 months the price changed by +7.0%, with an annualised volatility of 79% and a largest fall of 48%. Hard red flags in our rules-based screen: Financial distress.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Return on assetsweighs on the score · better than 4% of peers
- Piotroski F-scoreweighs on the score · better than 8% of peers
- Volatility (1 y)weighs on the score · better than 19% of peers
Red flags and notes
- Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Caution. Share count growing more than 10 % a year over three years. More in the glossary → Share count growing more than 10 % a year over three years.
- Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.
- Caution. Book equity is below zero. More in the glossary → Book equity is below zero.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- Free-cash-flow yield
- −12.2%
- Market cap (EUR)
- €968.9M
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- −23.4%
- 1 month
- −27.9%
- 1 year
- +7.0%
- Volatility, 1 yr
- 78.9%
- Max drawdown, 1 yr
- −48.3%
- Beta
- 1.16
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| RAPPRapport Therapeutics Inc. | 1/10 | 0.0% | −22.3% |
|---|---|---|---|
| IRMDiRadimed Corporation | 7/10 | 0.9% | 6.6% |
| HROWHarrow Inc. | 2/10 | 0.0% | −23.0% |
| MNKDMannKind Corporation | 1/10 | 0.0% | −35.3% |
| JANXJanux Therapeutics Inc. | 1/10 | 0.0% | −39.3% |
| LTGOLatigo Biotherapeutics Inc. | —/10 | 0.0% | — |
| MLTXMoonLake Immunotherapeutics | 1/10 | 0.0% | 25.4% |
| CBLLCeriBell Inc. | 2/10 | 0.0% | 112.2% |
News and filings
- Inhibrx Biosciences, Inc.: 8-K — Regulation FD disclosure
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 28 Sep 2026
- Inhibrx Biosciences, Inc.: 8-K — Regulation FD disclosure; other events
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 8 Sep 2026
- Inhibrx Biosciences, Inc.: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 13 Aug 2026
- Inhibrx Biosciences, Inc.: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 13 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.